nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CYP3A4—type 2 diabetes mellitus	0.266	1	CbGaD
Cevimeline—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.04	0.101	CbGbCtD
Cevimeline—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0395	0.0998	CbGbCtD
Cevimeline—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0369	0.0934	CbGbCtD
Cevimeline—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0352	0.089	CbGbCtD
Cevimeline—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0322	0.0814	CbGbCtD
Cevimeline—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0303	0.0767	CbGbCtD
Cevimeline—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0291	0.0735	CbGbCtD
Cevimeline—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0281	0.0711	CbGbCtD
Cevimeline—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0254	0.0643	CbGbCtD
Cevimeline—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0193	0.0488	CbGbCtD
Cevimeline—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0185	0.0467	CbGbCtD
Cevimeline—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0185	0.0467	CbGbCtD
Cevimeline—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0175	0.0442	CbGbCtD
Cevimeline—CYP3A4—Glyburide—type 2 diabetes mellitus	0.013	0.0329	CbGbCtD
Cevimeline—CYP3A4—Losartan—type 2 diabetes mellitus	0.0119	0.0301	CbGbCtD
Cevimeline—Oedema—Metformin—type 2 diabetes mellitus	8.57e-05	0.000327	CcSEcCtD
Cevimeline—Tinnitus—Ramipril—type 2 diabetes mellitus	8.57e-05	0.000327	CcSEcCtD
Cevimeline—Hypertension—Irbesartan—type 2 diabetes mellitus	8.56e-05	0.000327	CcSEcCtD
Cevimeline—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	8.54e-05	0.000326	CcSEcCtD
Cevimeline—Flushing—Ramipril—type 2 diabetes mellitus	8.53e-05	0.000325	CcSEcCtD
Cevimeline—Infection—Metformin—type 2 diabetes mellitus	8.52e-05	0.000325	CcSEcCtD
Cevimeline—Insomnia—Valsartan—type 2 diabetes mellitus	8.52e-05	0.000325	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	8.48e-05	0.000323	CcSEcCtD
Cevimeline—Paraesthesia—Valsartan—type 2 diabetes mellitus	8.45e-05	0.000323	CcSEcCtD
Cevimeline—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	8.45e-05	0.000322	CcSEcCtD
Cevimeline—Chest pain—Irbesartan—type 2 diabetes mellitus	8.44e-05	0.000322	CcSEcCtD
Cevimeline—Arthralgia—Irbesartan—type 2 diabetes mellitus	8.44e-05	0.000322	CcSEcCtD
Cevimeline—Myalgia—Irbesartan—type 2 diabetes mellitus	8.44e-05	0.000322	CcSEcCtD
Cevimeline—Shock—Metformin—type 2 diabetes mellitus	8.44e-05	0.000322	CcSEcCtD
Cevimeline—Insomnia—Orlistat—type 2 diabetes mellitus	8.42e-05	0.000321	CcSEcCtD
Cevimeline—Malaise—Losartan—type 2 diabetes mellitus	8.41e-05	0.000321	CcSEcCtD
Cevimeline—Anxiety—Irbesartan—type 2 diabetes mellitus	8.41e-05	0.000321	CcSEcCtD
Cevimeline—Hypersensitivity—Glyburide—type 2 diabetes mellitus	8.41e-05	0.000321	CcSEcCtD
Cevimeline—Nervous system disorder—Metformin—type 2 diabetes mellitus	8.41e-05	0.000321	CcSEcCtD
Cevimeline—Thrombocytopenia—Metformin—type 2 diabetes mellitus	8.4e-05	0.00032	CcSEcCtD
Cevimeline—Dyspnoea—Valsartan—type 2 diabetes mellitus	8.39e-05	0.00032	CcSEcCtD
Cevimeline—Vertigo—Losartan—type 2 diabetes mellitus	8.38e-05	0.00032	CcSEcCtD
Cevimeline—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	8.38e-05	0.00032	CcSEcCtD
Cevimeline—Somnolence—Valsartan—type 2 diabetes mellitus	8.37e-05	0.000319	CcSEcCtD
Cevimeline—Syncope—Losartan—type 2 diabetes mellitus	8.37e-05	0.000319	CcSEcCtD
Cevimeline—Paraesthesia—Orlistat—type 2 diabetes mellitus	8.35e-05	0.000319	CcSEcCtD
Cevimeline—Leukopenia—Losartan—type 2 diabetes mellitus	8.35e-05	0.000319	CcSEcCtD
Cevimeline—Discomfort—Irbesartan—type 2 diabetes mellitus	8.34e-05	0.000318	CcSEcCtD
Cevimeline—Skin disorder—Metformin—type 2 diabetes mellitus	8.33e-05	0.000318	CcSEcCtD
Cevimeline—Hyperhidrosis—Metformin—type 2 diabetes mellitus	8.29e-05	0.000316	CcSEcCtD
Cevimeline—Dyspepsia—Valsartan—type 2 diabetes mellitus	8.29e-05	0.000316	CcSEcCtD
Cevimeline—Dizziness—Bromocriptine—type 2 diabetes mellitus	8.26e-05	0.000315	CcSEcCtD
Cevimeline—Palpitations—Losartan—type 2 diabetes mellitus	8.25e-05	0.000315	CcSEcCtD
Cevimeline—Nausea—Glimepiride—type 2 diabetes mellitus	8.22e-05	0.000314	CcSEcCtD
Cevimeline—Arrhythmia—Ramipril—type 2 diabetes mellitus	8.21e-05	0.000313	CcSEcCtD
Cevimeline—Loss of consciousness—Losartan—type 2 diabetes mellitus	8.2e-05	0.000313	CcSEcCtD
Cevimeline—Nausea—Sitagliptin—type 2 diabetes mellitus	8.19e-05	0.000313	CcSEcCtD
Cevimeline—Dyspepsia—Orlistat—type 2 diabetes mellitus	8.19e-05	0.000312	CcSEcCtD
Cevimeline—Asthenia—Glyburide—type 2 diabetes mellitus	8.19e-05	0.000312	CcSEcCtD
Cevimeline—Decreased appetite—Valsartan—type 2 diabetes mellitus	8.19e-05	0.000312	CcSEcCtD
Cevimeline—Anorexia—Metformin—type 2 diabetes mellitus	8.17e-05	0.000312	CcSEcCtD
Cevimeline—Cough—Losartan—type 2 diabetes mellitus	8.14e-05	0.000311	CcSEcCtD
Cevimeline—Urticaria—Gliclazide—type 2 diabetes mellitus	8.14e-05	0.000311	CcSEcCtD
Cevimeline—Alopecia—Ramipril—type 2 diabetes mellitus	8.12e-05	0.00031	CcSEcCtD
Cevimeline—Fatigue—Valsartan—type 2 diabetes mellitus	8.12e-05	0.00031	CcSEcCtD
Cevimeline—Abdominal pain—Gliclazide—type 2 diabetes mellitus	8.1e-05	0.000309	CcSEcCtD
Cevimeline—Body temperature increased—Gliclazide—type 2 diabetes mellitus	8.1e-05	0.000309	CcSEcCtD
Cevimeline—Oedema—Irbesartan—type 2 diabetes mellitus	8.09e-05	0.000309	CcSEcCtD
Cevimeline—Decreased appetite—Orlistat—type 2 diabetes mellitus	8.09e-05	0.000309	CcSEcCtD
Cevimeline—Pruritus—Glyburide—type 2 diabetes mellitus	8.07e-05	0.000308	CcSEcCtD
Cevimeline—Constipation—Valsartan—type 2 diabetes mellitus	8.05e-05	0.000307	CcSEcCtD
Cevimeline—Infection—Irbesartan—type 2 diabetes mellitus	8.04e-05	0.000307	CcSEcCtD
Cevimeline—Fatigue—Orlistat—type 2 diabetes mellitus	8.02e-05	0.000306	CcSEcCtD
Cevimeline—Hypotension—Metformin—type 2 diabetes mellitus	8.01e-05	0.000306	CcSEcCtD
Cevimeline—Malnutrition—Ramipril—type 2 diabetes mellitus	8e-05	0.000305	CcSEcCtD
Cevimeline—Shock—Irbesartan—type 2 diabetes mellitus	7.96e-05	0.000304	CcSEcCtD
Cevimeline—Pain—Orlistat—type 2 diabetes mellitus	7.96e-05	0.000304	CcSEcCtD
Cevimeline—Chest pain—Losartan—type 2 diabetes mellitus	7.94e-05	0.000303	CcSEcCtD
Cevimeline—Arthralgia—Losartan—type 2 diabetes mellitus	7.94e-05	0.000303	CcSEcCtD
Cevimeline—Myalgia—Losartan—type 2 diabetes mellitus	7.94e-05	0.000303	CcSEcCtD
Cevimeline—Vomiting—Bromocriptine—type 2 diabetes mellitus	7.94e-05	0.000303	CcSEcCtD
Cevimeline—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	7.94e-05	0.000303	CcSEcCtD
Cevimeline—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	7.92e-05	0.000302	CcSEcCtD
Cevimeline—Anxiety—Losartan—type 2 diabetes mellitus	7.92e-05	0.000302	CcSEcCtD
Cevimeline—Tachycardia—Irbesartan—type 2 diabetes mellitus	7.9e-05	0.000301	CcSEcCtD
Cevimeline—Rash—Bromocriptine—type 2 diabetes mellitus	7.87e-05	0.0003	CcSEcCtD
Cevimeline—Dermatitis—Bromocriptine—type 2 diabetes mellitus	7.86e-05	0.0003	CcSEcCtD
Cevimeline—Skin disorder—Irbesartan—type 2 diabetes mellitus	7.86e-05	0.0003	CcSEcCtD
Cevimeline—Discomfort—Losartan—type 2 diabetes mellitus	7.85e-05	0.000299	CcSEcCtD
Cevimeline—Dysgeusia—Ramipril—type 2 diabetes mellitus	7.83e-05	0.000299	CcSEcCtD
Cevimeline—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	7.82e-05	0.000298	CcSEcCtD
Cevimeline—Headache—Bromocriptine—type 2 diabetes mellitus	7.82e-05	0.000298	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	7.81e-05	0.000298	CcSEcCtD
Cevimeline—Diarrhoea—Glyburide—type 2 diabetes mellitus	7.81e-05	0.000298	CcSEcCtD
Cevimeline—Anorexia—Irbesartan—type 2 diabetes mellitus	7.71e-05	0.000294	CcSEcCtD
Cevimeline—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	7.7e-05	0.000294	CcSEcCtD
Cevimeline—Paraesthesia—Metformin—type 2 diabetes mellitus	7.7e-05	0.000294	CcSEcCtD
Cevimeline—Muscle spasms—Ramipril—type 2 diabetes mellitus	7.69e-05	0.000293	CcSEcCtD
Cevimeline—Confusional state—Losartan—type 2 diabetes mellitus	7.68e-05	0.000293	CcSEcCtD
Cevimeline—Feeling abnormal—Orlistat—type 2 diabetes mellitus	7.67e-05	0.000293	CcSEcCtD
Cevimeline—Dyspnoea—Metformin—type 2 diabetes mellitus	7.64e-05	0.000292	CcSEcCtD
Cevimeline—Somnolence—Metformin—type 2 diabetes mellitus	7.62e-05	0.000291	CcSEcCtD
Cevimeline—Oedema—Losartan—type 2 diabetes mellitus	7.62e-05	0.000291	CcSEcCtD
Cevimeline—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	7.61e-05	0.00029	CcSEcCtD
Cevimeline—Infection—Losartan—type 2 diabetes mellitus	7.57e-05	0.000289	CcSEcCtD
Cevimeline—Hypotension—Irbesartan—type 2 diabetes mellitus	7.56e-05	0.000288	CcSEcCtD
Cevimeline—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	7.55e-05	0.000288	CcSEcCtD
Cevimeline—Dyspepsia—Metformin—type 2 diabetes mellitus	7.55e-05	0.000288	CcSEcCtD
Cevimeline—Tremor—Ramipril—type 2 diabetes mellitus	7.5e-05	0.000286	CcSEcCtD
Cevimeline—Shock—Losartan—type 2 diabetes mellitus	7.49e-05	0.000286	CcSEcCtD
Cevimeline—Urticaria—Valsartan—type 2 diabetes mellitus	7.48e-05	0.000285	CcSEcCtD
Cevimeline—Nervous system disorder—Losartan—type 2 diabetes mellitus	7.47e-05	0.000285	CcSEcCtD
Cevimeline—Thrombocytopenia—Losartan—type 2 diabetes mellitus	7.46e-05	0.000284	CcSEcCtD
Cevimeline—Decreased appetite—Metformin—type 2 diabetes mellitus	7.45e-05	0.000284	CcSEcCtD
Cevimeline—Abdominal pain—Valsartan—type 2 diabetes mellitus	7.44e-05	0.000284	CcSEcCtD
Cevimeline—Tachycardia—Losartan—type 2 diabetes mellitus	7.43e-05	0.000284	CcSEcCtD
Cevimeline—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	7.42e-05	0.000283	CcSEcCtD
Cevimeline—Nausea—Bromocriptine—type 2 diabetes mellitus	7.42e-05	0.000283	CcSEcCtD
Cevimeline—Fatigue—Metformin—type 2 diabetes mellitus	7.39e-05	0.000282	CcSEcCtD
Cevimeline—Urticaria—Orlistat—type 2 diabetes mellitus	7.39e-05	0.000282	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	7.37e-05	0.000281	CcSEcCtD
Cevimeline—Hyperhidrosis—Losartan—type 2 diabetes mellitus	7.36e-05	0.000281	CcSEcCtD
Cevimeline—Abdominal pain—Orlistat—type 2 diabetes mellitus	7.35e-05	0.000281	CcSEcCtD
Cevimeline—Body temperature increased—Orlistat—type 2 diabetes mellitus	7.35e-05	0.000281	CcSEcCtD
Cevimeline—Asthenia—Gliclazide—type 2 diabetes mellitus	7.35e-05	0.000281	CcSEcCtD
Cevimeline—Agitation—Ramipril—type 2 diabetes mellitus	7.35e-05	0.000281	CcSEcCtD
Cevimeline—Constipation—Metformin—type 2 diabetes mellitus	7.33e-05	0.00028	CcSEcCtD
Cevimeline—Paraesthesia—Irbesartan—type 2 diabetes mellitus	7.27e-05	0.000277	CcSEcCtD
Cevimeline—Anorexia—Losartan—type 2 diabetes mellitus	7.26e-05	0.000277	CcSEcCtD
Cevimeline—Vomiting—Glyburide—type 2 diabetes mellitus	7.26e-05	0.000277	CcSEcCtD
Cevimeline—Pruritus—Gliclazide—type 2 diabetes mellitus	7.25e-05	0.000277	CcSEcCtD
Cevimeline—Malaise—Ramipril—type 2 diabetes mellitus	7.21e-05	0.000275	CcSEcCtD
Cevimeline—Dyspnoea—Irbesartan—type 2 diabetes mellitus	7.21e-05	0.000275	CcSEcCtD
Cevimeline—Rash—Glyburide—type 2 diabetes mellitus	7.2e-05	0.000275	CcSEcCtD
Cevimeline—Somnolence—Irbesartan—type 2 diabetes mellitus	7.19e-05	0.000274	CcSEcCtD
Cevimeline—Dermatitis—Glyburide—type 2 diabetes mellitus	7.19e-05	0.000274	CcSEcCtD
Cevimeline—Vertigo—Ramipril—type 2 diabetes mellitus	7.19e-05	0.000274	CcSEcCtD
Cevimeline—Syncope—Ramipril—type 2 diabetes mellitus	7.17e-05	0.000274	CcSEcCtD
Cevimeline—Leukopenia—Ramipril—type 2 diabetes mellitus	7.16e-05	0.000273	CcSEcCtD
Cevimeline—Headache—Glyburide—type 2 diabetes mellitus	7.15e-05	0.000273	CcSEcCtD
Cevimeline—Dyspepsia—Irbesartan—type 2 diabetes mellitus	7.12e-05	0.000272	CcSEcCtD
Cevimeline—Hypotension—Losartan—type 2 diabetes mellitus	7.12e-05	0.000271	CcSEcCtD
Cevimeline—Palpitations—Ramipril—type 2 diabetes mellitus	7.07e-05	0.00027	CcSEcCtD
Cevimeline—Feeling abnormal—Metformin—type 2 diabetes mellitus	7.07e-05	0.00027	CcSEcCtD
Cevimeline—Decreased appetite—Irbesartan—type 2 diabetes mellitus	7.03e-05	0.000268	CcSEcCtD
Cevimeline—Loss of consciousness—Ramipril—type 2 diabetes mellitus	7.03e-05	0.000268	CcSEcCtD
Cevimeline—Diarrhoea—Gliclazide—type 2 diabetes mellitus	7.01e-05	0.000268	CcSEcCtD
Cevimeline—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	7.01e-05	0.000268	CcSEcCtD
Cevimeline—Cough—Ramipril—type 2 diabetes mellitus	6.98e-05	0.000266	CcSEcCtD
Cevimeline—Fatigue—Irbesartan—type 2 diabetes mellitus	6.98e-05	0.000266	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	6.94e-05	0.000265	CcSEcCtD
Cevimeline—Hypersensitivity—Valsartan—type 2 diabetes mellitus	6.94e-05	0.000265	CcSEcCtD
Cevimeline—Convulsion—Ramipril—type 2 diabetes mellitus	6.93e-05	0.000264	CcSEcCtD
Cevimeline—Pain—Irbesartan—type 2 diabetes mellitus	6.92e-05	0.000264	CcSEcCtD
Cevimeline—Constipation—Irbesartan—type 2 diabetes mellitus	6.92e-05	0.000264	CcSEcCtD
Cevimeline—Insomnia—Losartan—type 2 diabetes mellitus	6.89e-05	0.000263	CcSEcCtD
Cevimeline—Hypersensitivity—Orlistat—type 2 diabetes mellitus	6.85e-05	0.000262	CcSEcCtD
Cevimeline—Paraesthesia—Losartan—type 2 diabetes mellitus	6.84e-05	0.000261	CcSEcCtD
Cevimeline—Urticaria—Metformin—type 2 diabetes mellitus	6.81e-05	0.00026	CcSEcCtD
Cevimeline—Chest pain—Ramipril—type 2 diabetes mellitus	6.81e-05	0.00026	CcSEcCtD
Cevimeline—Arthralgia—Ramipril—type 2 diabetes mellitus	6.81e-05	0.00026	CcSEcCtD
Cevimeline—Myalgia—Ramipril—type 2 diabetes mellitus	6.81e-05	0.00026	CcSEcCtD
Cevimeline—Dyspnoea—Losartan—type 2 diabetes mellitus	6.79e-05	0.000259	CcSEcCtD
Cevimeline—Anxiety—Ramipril—type 2 diabetes mellitus	6.79e-05	0.000259	CcSEcCtD
Cevimeline—Nausea—Glyburide—type 2 diabetes mellitus	6.78e-05	0.000259	CcSEcCtD
Cevimeline—Abdominal pain—Metformin—type 2 diabetes mellitus	6.78e-05	0.000259	CcSEcCtD
Cevimeline—Dizziness—Gliclazide—type 2 diabetes mellitus	6.78e-05	0.000259	CcSEcCtD
Cevimeline—Somnolence—Losartan—type 2 diabetes mellitus	6.77e-05	0.000258	CcSEcCtD
Cevimeline—Asthenia—Valsartan—type 2 diabetes mellitus	6.76e-05	0.000258	CcSEcCtD
Cevimeline—Discomfort—Ramipril—type 2 diabetes mellitus	6.73e-05	0.000257	CcSEcCtD
Cevimeline—Dyspepsia—Losartan—type 2 diabetes mellitus	6.7e-05	0.000256	CcSEcCtD
Cevimeline—Asthenia—Orlistat—type 2 diabetes mellitus	6.68e-05	0.000255	CcSEcCtD
Cevimeline—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	6.67e-05	0.000254	CcSEcCtD
Cevimeline—Pruritus—Valsartan—type 2 diabetes mellitus	6.66e-05	0.000254	CcSEcCtD
Cevimeline—Decreased appetite—Losartan—type 2 diabetes mellitus	6.62e-05	0.000253	CcSEcCtD
Cevimeline—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	6.62e-05	0.000252	CcSEcCtD
Cevimeline—Confusional state—Ramipril—type 2 diabetes mellitus	6.58e-05	0.000251	CcSEcCtD
Cevimeline—Pruritus—Orlistat—type 2 diabetes mellitus	6.58e-05	0.000251	CcSEcCtD
Cevimeline—Fatigue—Losartan—type 2 diabetes mellitus	6.57e-05	0.00025	CcSEcCtD
Cevimeline—Oedema—Ramipril—type 2 diabetes mellitus	6.53e-05	0.000249	CcSEcCtD
Cevimeline—Vomiting—Gliclazide—type 2 diabetes mellitus	6.52e-05	0.000249	CcSEcCtD
Cevimeline—Pain—Losartan—type 2 diabetes mellitus	6.51e-05	0.000248	CcSEcCtD
Cevimeline—Constipation—Losartan—type 2 diabetes mellitus	6.51e-05	0.000248	CcSEcCtD
Cevimeline—Rash—Gliclazide—type 2 diabetes mellitus	6.46e-05	0.000247	CcSEcCtD
Cevimeline—Dermatitis—Gliclazide—type 2 diabetes mellitus	6.46e-05	0.000246	CcSEcCtD
Cevimeline—Diarrhoea—Valsartan—type 2 diabetes mellitus	6.44e-05	0.000246	CcSEcCtD
Cevimeline—Urticaria—Irbesartan—type 2 diabetes mellitus	6.43e-05	0.000245	CcSEcCtD
Cevimeline—Shock—Ramipril—type 2 diabetes mellitus	6.42e-05	0.000245	CcSEcCtD
Cevimeline—Headache—Gliclazide—type 2 diabetes mellitus	6.42e-05	0.000245	CcSEcCtD
Cevimeline—Nervous system disorder—Ramipril—type 2 diabetes mellitus	6.4e-05	0.000244	CcSEcCtD
Cevimeline—Abdominal pain—Irbesartan—type 2 diabetes mellitus	6.4e-05	0.000244	CcSEcCtD
Cevimeline—Body temperature increased—Irbesartan—type 2 diabetes mellitus	6.4e-05	0.000244	CcSEcCtD
Cevimeline—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	6.39e-05	0.000244	CcSEcCtD
Cevimeline—Tachycardia—Ramipril—type 2 diabetes mellitus	6.37e-05	0.000243	CcSEcCtD
Cevimeline—Diarrhoea—Orlistat—type 2 diabetes mellitus	6.37e-05	0.000243	CcSEcCtD
Cevimeline—Skin disorder—Ramipril—type 2 diabetes mellitus	6.34e-05	0.000242	CcSEcCtD
Cevimeline—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	6.31e-05	0.000241	CcSEcCtD
Cevimeline—Feeling abnormal—Losartan—type 2 diabetes mellitus	6.28e-05	0.000239	CcSEcCtD
Cevimeline—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	6.23e-05	0.000238	CcSEcCtD
Cevimeline—Dizziness—Valsartan—type 2 diabetes mellitus	6.23e-05	0.000238	CcSEcCtD
Cevimeline—Anorexia—Ramipril—type 2 diabetes mellitus	6.22e-05	0.000237	CcSEcCtD
Cevimeline—Dizziness—Orlistat—type 2 diabetes mellitus	6.15e-05	0.000235	CcSEcCtD
Cevimeline—Asthenia—Metformin—type 2 diabetes mellitus	6.15e-05	0.000235	CcSEcCtD
Cevimeline—Hypotension—Ramipril—type 2 diabetes mellitus	6.1e-05	0.000233	CcSEcCtD
Cevimeline—Nausea—Gliclazide—type 2 diabetes mellitus	6.09e-05	0.000232	CcSEcCtD
Cevimeline—Pruritus—Metformin—type 2 diabetes mellitus	6.07e-05	0.000231	CcSEcCtD
Cevimeline—Urticaria—Losartan—type 2 diabetes mellitus	6.05e-05	0.000231	CcSEcCtD
Cevimeline—Body temperature increased—Losartan—type 2 diabetes mellitus	6.02e-05	0.00023	CcSEcCtD
Cevimeline—Abdominal pain—Losartan—type 2 diabetes mellitus	6.02e-05	0.00023	CcSEcCtD
Cevimeline—Vomiting—Valsartan—type 2 diabetes mellitus	5.99e-05	0.000228	CcSEcCtD
Cevimeline—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	5.96e-05	0.000227	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	5.95e-05	0.000227	CcSEcCtD
Cevimeline—Rash—Valsartan—type 2 diabetes mellitus	5.94e-05	0.000227	CcSEcCtD
Cevimeline—Dermatitis—Valsartan—type 2 diabetes mellitus	5.93e-05	0.000226	CcSEcCtD
Cevimeline—Vomiting—Orlistat—type 2 diabetes mellitus	5.92e-05	0.000226	CcSEcCtD
Cevimeline—Insomnia—Ramipril—type 2 diabetes mellitus	5.91e-05	0.000225	CcSEcCtD
Cevimeline—Headache—Valsartan—type 2 diabetes mellitus	5.9e-05	0.000225	CcSEcCtD
Cevimeline—Diarrhoea—Metformin—type 2 diabetes mellitus	5.87e-05	0.000224	CcSEcCtD
Cevimeline—Rash—Orlistat—type 2 diabetes mellitus	5.87e-05	0.000224	CcSEcCtD
Cevimeline—Paraesthesia—Ramipril—type 2 diabetes mellitus	5.86e-05	0.000224	CcSEcCtD
Cevimeline—Dermatitis—Orlistat—type 2 diabetes mellitus	5.86e-05	0.000224	CcSEcCtD
Cevimeline—Headache—Orlistat—type 2 diabetes mellitus	5.83e-05	0.000222	CcSEcCtD
Cevimeline—Dyspnoea—Ramipril—type 2 diabetes mellitus	5.82e-05	0.000222	CcSEcCtD
Cevimeline—Asthenia—Irbesartan—type 2 diabetes mellitus	5.81e-05	0.000222	CcSEcCtD
Cevimeline—Somnolence—Ramipril—type 2 diabetes mellitus	5.8e-05	0.000221	CcSEcCtD
Cevimeline—Dyspepsia—Ramipril—type 2 diabetes mellitus	5.75e-05	0.000219	CcSEcCtD
Cevimeline—Pruritus—Irbesartan—type 2 diabetes mellitus	5.72e-05	0.000218	CcSEcCtD
Cevimeline—Decreased appetite—Ramipril—type 2 diabetes mellitus	5.68e-05	0.000217	CcSEcCtD
Cevimeline—Dizziness—Metformin—type 2 diabetes mellitus	5.67e-05	0.000216	CcSEcCtD
Cevimeline—Fatigue—Ramipril—type 2 diabetes mellitus	5.63e-05	0.000215	CcSEcCtD
Cevimeline—Hypersensitivity—Losartan—type 2 diabetes mellitus	5.61e-05	0.000214	CcSEcCtD
Cevimeline—Nausea—Valsartan—type 2 diabetes mellitus	5.59e-05	0.000213	CcSEcCtD
Cevimeline—Constipation—Ramipril—type 2 diabetes mellitus	5.58e-05	0.000213	CcSEcCtD
Cevimeline—Diarrhoea—Irbesartan—type 2 diabetes mellitus	5.54e-05	0.000211	CcSEcCtD
Cevimeline—Nausea—Orlistat—type 2 diabetes mellitus	5.53e-05	0.000211	CcSEcCtD
Cevimeline—Asthenia—Losartan—type 2 diabetes mellitus	5.46e-05	0.000208	CcSEcCtD
Cevimeline—Vomiting—Metformin—type 2 diabetes mellitus	5.45e-05	0.000208	CcSEcCtD
Cevimeline—Rash—Metformin—type 2 diabetes mellitus	5.41e-05	0.000206	CcSEcCtD
Cevimeline—Dermatitis—Metformin—type 2 diabetes mellitus	5.4e-05	0.000206	CcSEcCtD
Cevimeline—Pruritus—Losartan—type 2 diabetes mellitus	5.39e-05	0.000206	CcSEcCtD
Cevimeline—Feeling abnormal—Ramipril—type 2 diabetes mellitus	5.38e-05	0.000205	CcSEcCtD
Cevimeline—Headache—Metformin—type 2 diabetes mellitus	5.37e-05	0.000205	CcSEcCtD
Cevimeline—Dizziness—Irbesartan—type 2 diabetes mellitus	5.35e-05	0.000204	CcSEcCtD
Cevimeline—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	5.34e-05	0.000204	CcSEcCtD
Cevimeline—Diarrhoea—Losartan—type 2 diabetes mellitus	5.21e-05	0.000199	CcSEcCtD
Cevimeline—Urticaria—Ramipril—type 2 diabetes mellitus	5.19e-05	0.000198	CcSEcCtD
Cevimeline—Abdominal pain—Ramipril—type 2 diabetes mellitus	5.16e-05	0.000197	CcSEcCtD
Cevimeline—Body temperature increased—Ramipril—type 2 diabetes mellitus	5.16e-05	0.000197	CcSEcCtD
Cevimeline—Vomiting—Irbesartan—type 2 diabetes mellitus	5.14e-05	0.000196	CcSEcCtD
Cevimeline—Rash—Irbesartan—type 2 diabetes mellitus	5.1e-05	0.000195	CcSEcCtD
Cevimeline—Dermatitis—Irbesartan—type 2 diabetes mellitus	5.1e-05	0.000194	CcSEcCtD
Cevimeline—Nausea—Metformin—type 2 diabetes mellitus	5.09e-05	0.000194	CcSEcCtD
Cevimeline—Headache—Irbesartan—type 2 diabetes mellitus	5.07e-05	0.000193	CcSEcCtD
Cevimeline—Dizziness—Losartan—type 2 diabetes mellitus	5.04e-05	0.000192	CcSEcCtD
Cevimeline—Vomiting—Losartan—type 2 diabetes mellitus	4.84e-05	0.000185	CcSEcCtD
Cevimeline—Hypersensitivity—Ramipril—type 2 diabetes mellitus	4.81e-05	0.000184	CcSEcCtD
Cevimeline—Nausea—Irbesartan—type 2 diabetes mellitus	4.81e-05	0.000183	CcSEcCtD
Cevimeline—Rash—Losartan—type 2 diabetes mellitus	4.8e-05	0.000183	CcSEcCtD
Cevimeline—Dermatitis—Losartan—type 2 diabetes mellitus	4.8e-05	0.000183	CcSEcCtD
Cevimeline—Headache—Losartan—type 2 diabetes mellitus	4.77e-05	0.000182	CcSEcCtD
Cevimeline—Asthenia—Ramipril—type 2 diabetes mellitus	4.68e-05	0.000179	CcSEcCtD
Cevimeline—Pruritus—Ramipril—type 2 diabetes mellitus	4.62e-05	0.000176	CcSEcCtD
Cevimeline—Nausea—Losartan—type 2 diabetes mellitus	4.52e-05	0.000173	CcSEcCtD
Cevimeline—Diarrhoea—Ramipril—type 2 diabetes mellitus	4.47e-05	0.00017	CcSEcCtD
Cevimeline—Dizziness—Ramipril—type 2 diabetes mellitus	4.32e-05	0.000165	CcSEcCtD
Cevimeline—Vomiting—Ramipril—type 2 diabetes mellitus	4.15e-05	0.000158	CcSEcCtD
Cevimeline—Rash—Ramipril—type 2 diabetes mellitus	4.12e-05	0.000157	CcSEcCtD
Cevimeline—Dermatitis—Ramipril—type 2 diabetes mellitus	4.11e-05	0.000157	CcSEcCtD
Cevimeline—Headache—Ramipril—type 2 diabetes mellitus	4.09e-05	0.000156	CcSEcCtD
Cevimeline—Nausea—Ramipril—type 2 diabetes mellitus	3.88e-05	0.000148	CcSEcCtD
Cevimeline—CHRM1—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.32e-05	0.000171	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.32e-05	0.000171	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.31e-05	0.00017	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.31e-05	0.00017	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.28e-05	0.000167	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.28e-05	0.000166	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.27e-05	0.000166	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GLP1R—type 2 diabetes mellitus	1.26e-05	0.000163	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GNB3—type 2 diabetes mellitus	1.26e-05	0.000163	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.26e-05	0.000163	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—HMOX1—type 2 diabetes mellitus	1.25e-05	0.000162	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.24e-05	0.000161	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.24e-05	0.000161	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.24e-05	0.000161	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.23e-05	0.00016	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CAT—type 2 diabetes mellitus	1.23e-05	0.00016	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.22e-05	0.000159	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GCG—type 2 diabetes mellitus	1.22e-05	0.000159	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.22e-05	0.000158	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GCG—type 2 diabetes mellitus	1.22e-05	0.000158	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.22e-05	0.000158	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.22e-05	0.000158	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.22e-05	0.000158	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.2e-05	0.000156	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.2e-05	0.000156	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.2e-05	0.000156	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—APOB—type 2 diabetes mellitus	1.2e-05	0.000155	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.19e-05	0.000155	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC2A2—type 2 diabetes mellitus	1.17e-05	0.000152	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	1.17e-05	0.000151	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	1.17e-05	0.000151	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTM1—type 2 diabetes mellitus	1.16e-05	0.000151	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	1.15e-05	0.000149	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	1.15e-05	0.000149	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.14e-05	0.000149	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—LPL—type 2 diabetes mellitus	1.14e-05	0.000148	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.14e-05	0.000148	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	1.13e-05	0.000146	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.12e-05	0.000146	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	1.12e-05	0.000146	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	1.12e-05	0.000146	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.12e-05	0.000146	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	1.12e-05	0.000145	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	1.12e-05	0.000145	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	1.12e-05	0.000145	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.12e-05	0.000145	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ADCY5—type 2 diabetes mellitus	1.12e-05	0.000145	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.12e-05	0.000145	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GPX1—type 2 diabetes mellitus	1.12e-05	0.000145	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	1.11e-05	0.000145	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	1.1e-05	0.000143	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	1.09e-05	0.000142	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CD36—type 2 diabetes mellitus	1.09e-05	0.000141	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	1.08e-05	0.000141	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	1.08e-05	0.000141	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	1.08e-05	0.000141	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	1.08e-05	0.00014	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PPP2CA—type 2 diabetes mellitus	1.07e-05	0.000139	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.06e-05	0.000138	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.06e-05	0.000138	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.05e-05	0.000137	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.05e-05	0.000136	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	1.04e-05	0.000135	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.04e-05	0.000135	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AVP—type 2 diabetes mellitus	1.04e-05	0.000135	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.04e-05	0.000135	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.03e-05	0.000134	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.03e-05	0.000134	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.03e-05	0.000134	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—MTHFR—type 2 diabetes mellitus	1.03e-05	0.000134	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.03e-05	0.000133	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.02e-05	0.000132	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	1.02e-05	0.000132	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.02e-05	0.000132	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PPARA—type 2 diabetes mellitus	1.01e-05	0.000131	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	1e-05	0.00013	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	1e-05	0.00013	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	1e-05	0.00013	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	1e-05	0.00013	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—APOB—type 2 diabetes mellitus	1e-05	0.00013	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1e-05	0.00013	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.97e-06	0.000129	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.88e-06	0.000128	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	9.86e-06	0.000128	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.85e-06	0.000128	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—AGT—type 2 diabetes mellitus	9.78e-06	0.000127	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	9.77e-06	0.000127	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CALM1—type 2 diabetes mellitus	9.61e-06	0.000125	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	9.59e-06	0.000125	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—APOE—type 2 diabetes mellitus	9.58e-06	0.000124	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	9.56e-06	0.000124	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—LPL—type 2 diabetes mellitus	9.56e-06	0.000124	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	9.54e-06	0.000124	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—APOA1—type 2 diabetes mellitus	9.47e-06	0.000123	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.39e-06	0.000122	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.36e-06	0.000122	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	9.22e-06	0.00012	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	9.22e-06	0.00012	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	9.22e-06	0.00012	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	9.22e-06	0.00012	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	9.19e-06	0.000119	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	9.08e-06	0.000118	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	9.08e-06	0.000118	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.99e-06	0.000117	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.97e-06	0.000116	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	8.86e-06	0.000115	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	8.84e-06	0.000115	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.83e-06	0.000115	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.8e-06	0.000114	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	8.71e-06	0.000113	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	8.71e-06	0.000113	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—C3—type 2 diabetes mellitus	8.63e-06	0.000112	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—C3—type 2 diabetes mellitus	8.6e-06	0.000112	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PPARG—type 2 diabetes mellitus	8.34e-06	0.000108	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.23e-06	0.000107	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	8.21e-06	0.000107	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.21e-06	0.000107	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.21e-06	0.000107	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	8.2e-06	0.000107	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.19e-06	0.000106	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—INS—type 2 diabetes mellitus	8.18e-06	0.000106	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AGT—type 2 diabetes mellitus	8.18e-06	0.000106	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.06e-06	0.000105	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.04e-06	0.000104	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	8.04e-06	0.000104	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	8.04e-06	0.000104	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—APOE—type 2 diabetes mellitus	8.01e-06	0.000104	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—LEP—type 2 diabetes mellitus	8.01e-06	0.000104	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.94e-06	0.000103	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.92e-06	0.000103	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	7.67e-06	9.96e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.58e-06	9.84e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.55e-06	9.81e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	7.51e-06	9.76e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	7.51e-06	9.76e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.51e-06	9.75e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	7.51e-06	9.75e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	7.5e-06	9.75e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	7.47e-06	9.71e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	7.37e-06	9.58e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	7.37e-06	9.57e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	7.32e-06	9.51e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	7.32e-06	9.51e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	7.32e-06	9.51e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	7.28e-06	9.45e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	7.18e-06	9.32e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	7.18e-06	9.32e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.17e-06	9.31e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	7.16e-06	9.3e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	7.15e-06	9.28e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.15e-06	9.28e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	7.06e-06	9.18e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	6.96e-06	9.04e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	6.86e-06	8.92e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	6.84e-06	8.89e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	6.83e-06	8.88e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.75e-06	8.77e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.73e-06	8.75e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	6.69e-06	8.69e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	6.67e-06	8.66e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.64e-06	8.63e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.64e-06	8.62e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.62e-06	8.6e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.61e-06	8.59e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.61e-06	8.58e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.59e-06	8.56e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	6.57e-06	8.53e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	6.57e-06	8.53e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	6.57e-06	8.53e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	6.56e-06	8.53e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	6.49e-06	8.43e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	6.45e-06	8.37e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	6.41e-06	8.33e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	6.39e-06	8.3e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.31e-06	8.19e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.29e-06	8.17e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	6.25e-06	8.12e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	6.15e-06	7.99e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	6.04e-06	7.84e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.02e-06	7.82e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.02e-06	7.82e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	6.01e-06	7.8e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6e-06	7.8e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	6e-06	7.8e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	5.94e-06	7.71e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	5.94e-06	7.71e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	5.85e-06	7.59e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	5.75e-06	7.47e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	5.73e-06	7.44e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	5.69e-06	7.4e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	5.69e-06	7.4e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	5.67e-06	7.36e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	5.66e-06	7.36e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	5.65e-06	7.34e-05	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.16e-06	6.7e-05	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.14e-06	6.68e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.11e-06	6.64e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.09e-06	6.62e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.08e-06	6.6e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.06e-06	6.58e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	4.99e-06	6.48e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	4.91e-06	6.38e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.91e-06	6.38e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	4.89e-06	6.36e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	4.88e-06	6.35e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.83e-06	6.27e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	4.82e-06	6.26e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.81e-06	6.25e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.78e-06	6.21e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.76e-06	6.19e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.68e-06	6.09e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	4.68e-06	6.08e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.67e-06	6.07e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	4.55e-06	5.91e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	4.49e-06	5.83e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	4.47e-06	5.8e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	4.45e-06	5.79e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	4.44e-06	5.77e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	4.37e-06	5.68e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	4.36e-06	5.66e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.34e-06	5.63e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.32e-06	5.62e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	4.29e-06	5.57e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	4.29e-06	5.57e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	4.25e-06	5.51e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	4.19e-06	5.45e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	4.02e-06	5.23e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.98e-06	5.17e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.97e-06	5.16e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.95e-06	5.13e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	3.92e-06	5.1e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.9e-06	5.07e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.89e-06	5.05e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.82e-06	4.97e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.76e-06	4.88e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.74e-06	4.87e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.7e-06	4.81e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	3.3e-06	4.29e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	3.26e-06	4.24e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	3.2e-06	4.16e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	3e-06	3.9e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	2.99e-06	3.88e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.93e-06	3.81e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.81e-06	3.64e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.81e-06	3.64e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.77e-06	3.6e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.76e-06	3.58e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.57e-06	3.33e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.97e-06	2.56e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.29e-06	1.68e-05	CbGpPWpGaD
